A New Fecal Calprotectin Test for Colorectal Neoplasia: Clinical Results and Comparison with Previous Method

References

• Young GP, St. John DJB. Community screening for colorectal cancer. Diagn Oncol 1995;4:65–72.
   Google Scholar
• Robinson MHE, Hardcastle JD, Moss SM, Amar SS, Chamberlain JO, Armitage NC, et al. The risk of screening: data from the Nottingham randomised controlled trial of fecal occult blood screening for colorectal cancer. Gut 1999;45:588–92.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Fagerhol MK, Aadland E, Schønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27(9):793–8.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993; 28(12):1073–6.
   Google Scholar
• Fagerhol MK, Dale I, Anderson I. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol 1980;24: 393–8.
   Google Scholar
• Fagerhol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (the L1 leukocyte protein). In: Smith VL, Dedman JR, editors. Stimulus response coupling: the role of intracellular calcium-binding proteins. Boca Raton, FL: CRC Press; 1990. p. 187–210.
   Google Scholar
• Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocytic protein calprotectin. J Clin Molec Pathol 1997; 50:113–23.
   PubMedGoogle Scholar
• Naess-Andresen CF, Egelandsdal B, Fagerhol MK. Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein). J Clin Pathol—Clin Molec Pathol Edn 1995;48(5):M278–84.
   Google Scholar
• Steinbakk M, Naess-Andresen C-F, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336 (8718):763–5.
   PubMed Web of Science ®Google Scholar
• Mikami M, Yamazaki M, Yui S. Kinetical analysis of tumor cell death-inducing mechanism by polymorphonuclear leukocyte-derived calprotectin: involvement of protein synthesis and generation of reactive oxygen species in target cells. Microbiol Immunol 1998;42:211–21.
   Google Scholar
• Kristinsson J, Røseth A, Fagerhol MK, Aadland E, Schjonsby H, Bormer OP, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998. p. 316–21.
   Google Scholar
• Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and cal-protectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34: 50–4.
   Google Scholar
• Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997. p. 176–80.
   Google Scholar
• Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000;46:0–5.
   Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362–6.
   PubMed Web of Science ®Google Scholar
• Meling T, Aabakken L, Røseth A, Osnes M. Faecal calprotectin-shedding after short term treatment with non-steroidal anti inflammatory drugs. Scand J Gastroenterol 1996;31:339–44.
   Google Scholar
• Tøn H, Brandsnes Ø, Holtlund J, Dale S, Johne B. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.
   PubMed Web of Science ®Google Scholar
• Kristinsson J, Nygaard K, Armbruster C, Kriwanek S, Ugstad MB, Fuglerud P. Fecal excretion of calprotectin in colorectal cancer [Abstract]. WC06, Vienna 1998.
   Google Scholar
• Kristinsson J, Nygaard K, Barstad S, Sauar J, Hofstad B, Stray N, et al. Screening of first degree relatives of patients operated for colorectal cancer [Abstract]. WC06, Vienna 1998.
   Google Scholar
• Wild D The immunoassay handbook. New York: Stockton Press; 1994.
   Google Scholar
• Marshall WJ Clinical chemistry. 3rd ed. London: Mosby; 1995.
   Google Scholar
• Young GP, St John DJB. Faecal occult blood tests: choice, usage and clinical applications. Clin Biochem Rev 1992;13:161–7.
   Google Scholar
• Nollau P, Wagener C. Detection of mutant alleles of tumor cells in stool: diagnostic value and perspectives of highly sensitive molecular methods for the early detection of colorectal cancer. In: Schmiegel W, Scholmerich J, editors. Colorectal cancer. Molecular mechanisms, premalignant state and its prevention. Vol 109. FALK Symposium; 1998. p. 135–43.
   Google Scholar
• Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995; 55:35–45.
   PubMed Web of Science ®Google Scholar
• Svennevig J-L, Lunde OC, Holter J. In situ analysis of the inflammatory cell infiltrates in colon carcinomas and in the normal colon wall. Acta Pathol Microbiol Immunol Scand Sect A 1982;90:131–7.
   Google Scholar
• Maxwell-Armstrong CA, Durrant LG, Robins RA, Galvin AM, Scholefield JH, Hardcastle JD. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut 1999;45: 593–8.
   Google Scholar
• Jaïs P, Kapel N, Chosidow D, Rupaire N, Rougier P, Lasser P, et al. Detection of protein p53 in the stool of patients with colorectal cancer. Gastroenterol Clin Biol 1997;21: 754–9.
   Google Scholar
• Jahn H, Jørgensen OD, Kronborg O, Fenger C. Can Hemoccult-II replace colonoscopy in surveillance after radical surgery for colorectal cancer and after polyppectomy? Dis Colon Rectum 1992;35:253–6.
   PubMed Web of Science ®Google Scholar
• Ravel R. Various factors affecting laboratory test interpretation. In: Ravel R, editor. Clinical laboratory medicine. St. Louis, MI: Mosby-Year Book, Inc.; 1995. p. 1–8.
   Google Scholar
• Silletti RP, Lee G, Ailey E. Role of stool screening tests in diagnosis of inflammatory bacterial enteritis and in selection of specimens likely to yield invasive enteric pathogens. J Clin Microbiol 1996;34:1161–5.
   Google Scholar
• Gilbert JA, Ahlquist AA, Mahoney DW, Zinsmeister AR, Rubin J, Ellefson RD. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 1996;31: 1001–5.
   PubMed Web of Science ®Google Scholar
• Sinatra MA, Young GP, St John DJ, Blake D, Ratnaike S. A study of laboratory based fecal occult blood testing in Melbourne, Australia. The Faecal Occult Blood Testing Study Group. J Gastroenterol Hepatol 1998;13:396–400.
   Google Scholar
• Wick MR, Mills SE, Swanson PE. Expression of ‘myelomono-cytic’ antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990;94:18–26.
   Google Scholar
• Brandtzæg P, Dale I, Gabrielsen TO. The leukocyte protein L1 (calprotectin): usefulness as an immunohistochemical marker antigen and putative biological function. Histopathology 1992; 21(2):191–6.
   Google Scholar
• Swidinski A, Khilkin M, Kerjaschki D, Schreiber S, Ortner M, Weber J, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998;115:281–6.
   PubMed Web of Science ®Google Scholar